A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

Conditions

• Herpes Genitalis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• ASP2151 — DRUG
  Oral administration.
• valacyclovir — DRUG
  Oral administration of active comparator.
• Placebo — DRUG
  Oral administration of placebo.

Study Details

A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.

Key Dates

Start date

Jun 21, 2007

Status verified

Dec 2017

Primary completion

Aug 12, 2008

Completion

Aug 12, 2008

Study Design

Enrollment

695 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: 1
  Oral administration of active comparator
• Placebo Comparator: 2
  Oral administration of placebo
• Experimental: 3
  Dosing regimen 1
• Experimental: 4
  Dosing regimen 2
• Experimental: 5
  Dosing regimen 3
• Experimental: 6
  Dosing regimen 4

Primary Outcome Measure

To compare the efficacy and safety of ASP2151 with valacyclovir and placebo in the acute treatment of recurrent genital Herpes Simplex Virus Infection [ Time Frame: 17 days ]

Locations (25)